Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cell Exosomes for Parkinson's Disease
NCT05152394Phase 1Recruiting
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Start
- Aug 2024
- Primary completion
- Jan 2027
- Modality
- Lipid-based Nanoparticles, Cell Therapies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of AlloEx in Parkinson's disease (PD), sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Primary endpoint: Adverse Events at 4 years. Started Aug 2024; status: recruiting.
02
Drugs
AlloEx
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05152394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05152394.